Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario
Yoanna I. Flores Vega, Diana L. Páramo González, Sofía C Alsina Sarmiento, Luis E. Alsina Tul, Iris B. Inguanzo Valdés, J Rodríguez Machado, Ángel Elejalde Larrinaga, Justo E Flores Rodríguez, Janet Lamadrid García, Danay Corrales Otero, Ramón Ropero Toirac, Tania Crombet, Elias A. Gracia Medina
Abstract
CIMAvax-EGF, as an EGF depleting immunotherapy used as switch-maintenance was safe and effective in patients with NSCLC.
Topics & Concepts
MedicineLung cancerAdverse effectInternal medicineOncologyAdjuvantEpidermal growth factorAdenocarcinomaCancerReceptorCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsCancer Research and Treatments